RIGL vs ROL · P/E 9.1, rev $179.3M vs P/E 41, rev $3.39B
Rigel Pharmaceuticals Inc (RIGL) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the RIGL and ROL stock pages for the full models.
Not investment advice.